A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
Petrylak D, Vogelzang N, Chatta G, Fleming M, Smith D, Appleman L, Hussain A, Modiano M, Singh P, Tagawa S, Gore I, McClay E, Mega A, Sartor A, Somer B, Wadlow R, Shore N, Stambler N, DiPippo V, Israel R. A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz). Journal Of Clinical Oncology 2015, 33: 144-144. DOI: 10.1200/jco.2015.33.7_suppl.144.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCTC declineProgressive metastatic castration-resistant prostate cancerCastration-resistant prostate cancerAntitumor activityMeasurable target lesionsNeuroendocrine serum markersPhase 2 studyPhase 2 trialPhase 1 studyHigh PSMA expressionProstate cancer cellsPSMA-positive cellsRadiologic responseHuman IgG1 antibodyPSA declineRadiologic evidenceElectrolyte imbalanceSerum markersCTC countEfficacy responseTarget lesionsProstate cancerPSMA expressionEnz treatment